Vir Biotechnology Stock Buy Hold or Sell Recommendation
| VIR Stock | USD 8.25 0.11 1.32% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Vir Biotechnology is 'Sell'. Macroaxis provides Vir Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VIR positions. The advice algorithm takes into account all of Vir Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Vir Biotechnology's buy or sell advice are summarized below:
Real Value 8.25 | Target Price 32.75 | Hype Value 8.25 | Market Value 8.25 | Naive Value 7.85 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vir Biotechnology given historical horizon and risk tolerance towards Vir Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for Vir Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Vir |
Execute Vir Biotechnology Buy or Sell Advice
The Vir recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vir Biotechnology. Macroaxis does not own or have any residual interests in Vir Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vir Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Vir Biotechnology Trading Alerts and Improvement Suggestions
| Vir Biotechnology generated a negative expected return over the last 90 days | |
| Vir Biotechnology has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B. | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 76.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 89942 shares by Svf Endurance Ltd of Vir Biotechnology at 25.1799 subject to Rule 16b-3 |
Vir Biotechnology Returns Distribution Density
The distribution of Vir Biotechnology's historical returns is an attempt to chart the uncertainty of Vir Biotechnology's future price movements. The chart of the probability distribution of Vir Biotechnology daily returns describes the distribution of returns around its average expected value. We use Vir Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vir Biotechnology returns is essential to provide solid investment advice for Vir Biotechnology.
| Mean Return | -0.29 | Value At Risk | -5.69 | Potential Upside | 4.84 | Standard Deviation | 3.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vir Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vir Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vir Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vir Biotechnology backward and forwards among themselves. Vir Biotechnology's institutional investor refers to the entity that pools money to purchase Vir Biotechnology's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Northern Trust Corp | 2023-12-31 | 937.3 K | D. E. Shaw & Co Lp | 2023-09-30 | 880.2 K | Charles Schwab Investment Management Inc | 2023-12-31 | 753.1 K | Bank Of New York Mellon Corp | 2023-12-31 | 720.9 K | Ubs Group Ag | 2023-12-31 | 526.2 K | Principal Financial Group Inc | 2023-12-31 | 507.6 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 468.3 K | Prudential Financial Inc | 2023-12-31 | 465.5 K | Blackrock Inc | 2023-12-31 | 16.9 M | Sb Investment Advisers (uk) Ltd | 2023-12-31 | 16.7 M |
Vir Biotechnology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (256.2M) | (3.5M) | (119.0M) | (1.2B) | 116.3M | 122.1M | |
| Change In Cash | 63.5M | 328.7M | (88.1M) | 504.6M | (606.5M) | (576.1M) | |
| Free Cash Flow | (138.6M) | (197.5M) | (69.4M) | 1.6B | (800.4M) | (760.3M) | |
| Depreciation | 4.5M | 5.4M | 5.8M | 6.8M | 19.5M | 20.4M | |
| Other Non Cash Items | 8.9M | 45.2M | (52.6M) | 388.4M | 11.2M | 10.6M | |
| Capital Expenditures | 8.9M | 6.5M | 21.8M | 68.0M | 21.6M | 21.7M | |
| Net Income | (174.7M) | (298.7M) | 528.6M | 515.8M | (615.1M) | (584.3M) | |
| End Period Cash Flow | 122.8M | 451.5M | 363.4M | 868.0M | 254.8M | 362.8M | |
| Change To Netincome | 32.3M | 45.2M | 46.4M | 475.3M | 546.6M | 573.9M |
Vir Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vir Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vir Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vir stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.4 | |
β | Beta against NYSE Composite | 2.30 | |
σ | Overall volatility | 3.48 | |
Ir | Information ratio | -0.1 |
Vir Biotechnology Volatility Alert
Vir Biotechnology exhibits very low volatility with skewness of 0.79 and kurtosis of 2.96. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vir Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vir Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vir Biotechnology Fundamentals Vs Peers
Comparing Vir Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vir Biotechnology's direct or indirect competition across all of the common fundamentals between Vir Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vir Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vir Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vir Biotechnology to competition |
| Fundamentals | Vir Biotechnology | Peer Average |
| Return On Equity | -0.34 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Operating Margin | (7.25) % | (5.51) % |
| Current Valuation | (269 M) | 16.62 B |
| Shares Outstanding | 135.03 M | 571.82 M |
| Shares Owned By Insiders | 14.22 % | 10.09 % |
| Shares Owned By Institutions | 76.27 % | 39.21 % |
| Number Of Shares Shorted | 4.96 M | 4.71 M |
| Price To Earning | 3.16 X | 28.72 X |
| Price To Book | 0.76 X | 9.51 X |
| Price To Sales | 14.05 X | 11.42 X |
| Revenue | 86.18 M | 9.43 B |
| Gross Profit | 1.03 B | 27.38 B |
| EBITDA | (641.55 M) | 3.9 B |
| Net Income | (615.06 M) | 570.98 M |
| Cash And Equivalents | 2.2 B | 2.7 B |
| Cash Per Share | 16.55 X | 5.01 X |
| Total Debt | 124.54 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 4.79 X | 2.16 X |
| Book Value Per Share | 11.80 X | 1.93 K |
| Cash Flow From Operations | (778.78 M) | 971.22 M |
| Short Ratio | 5.16 X | 4.00 X |
| Earnings Per Share | (4.59) X | 3.12 X |
| Price To Earnings To Growth | 1.14 X | 4.89 X |
| Target Price | 32.29 | |
| Number Of Employees | 587 | 18.84 K |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 1.13 B | 19.03 B |
| Total Asset | 1.96 B | 29.47 B |
| Retained Earnings | (237.82 M) | 9.33 B |
| Working Capital | 1.41 B | 1.48 B |
| Net Asset | 1.96 B |
Note: Disposition of 89942 shares by Svf Endurance Ltd of Vir Biotechnology at 25.1799 subject to Rule 16b-3 [view details]
Vir Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vir . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vir Biotechnology Buy or Sell Advice
When is the right time to buy or sell Vir Biotechnology? Buying financial instruments such as Vir Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 232.6M | 485.0M | 91.4M | 150.4M | Total Assets | 2.0B | 2.8B | 2.0B | 1.3B |
Use Investing Ideas to Build Portfolios
In addition to having Vir Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks - Regional Thematic Idea Now
Banks - Regional
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banks - Regional theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks - Regional Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vir Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Vir Stock analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Vir Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vir Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.585 | Earnings Share (4.59) | Revenue Per Share 0.643 | Quarterly Revenue Growth (0.66) | Return On Assets (0.17) |
The market value of Vir Biotechnology is measured differently than its book value, which is the value of Vir that is recorded on the company's balance sheet. Investors also form their own opinion of Vir Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Vir Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vir Biotechnology's market value can be influenced by many factors that don't directly affect Vir Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.